Targeting PIN1 in Pancreatic Tumor Microenvironment with Peptide Amphiphiles Unleashes Immune Checkpoint Therapy
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Yuanyuan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery I, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Microenvironment, Peptides, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Tian Yuan Mathematical Foundation.
Abstract (Originalsprache)
Pancreatic cancer (PC) is a highly aggressive malignancy with a dismal 5‐year survival rate of only 12%. Currently, no effective therapeutic strategies can improve the prognosis of pancreatic cancer. The activation of quiescent pancreatic stellate cells (PSCs) and their crosstalk with pancreatic cancer cells (PCCs) lead to the formation of a fibrotic physical barrier and an immunosuppressive tumor microenvironment (TME), which severely impede drug delivery and penetration. To improve PC treatment, a dual‐targeting strategy capable of simultaneously acting on PCCs and PSCs is urgently needed to revert activated PSCs (aPSCs) to their quiescent state and suppress the proliferation of PCCs. KPT‐6566, a small‐molecule inhibitor, shifts PSCs from an activated to a quiescent state, reprograms the tumor immune microenvironment (TIME) to enhance anti‐PD‐L1 immunotherapy efficacy, suppresses PCCs proliferation, and induces PD‐L1 expression on PCC surfaces, thereby increasing sensitivity to PD‐L1‐targeted therapies. This study designs two amphiphilic peptides, C16‐LLGG‐COO‐ D PPA‐1(DPPA‐1@PA) and DSPE‐PEG‐NHS‐CGKRK(CGKRK@PA), which can co‐assemble to encapsulate KPT‐6566 and finally form a peptide‐based nanoparticle termed DP‐KPT‐CG@PA. This nanoparticle precisely targets PCCs and PSCs to co‐deliver KPT‐6566, while synergizing with a PD‐L1‐blocking peptide to initiate immune checkpoint blockade therapy, thereby enhancing response rates to pancreatic cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery I, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Institute of Digital Intelligent Minimally Invasive Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, China.
- South China Institute of National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments, Guangzhou, China.
- Shaanxi Provincial People's Hospital, 256 West Youyi Road, Xi'an, Shaanxi, 710061, China.
ORCID-Profile: Chihua Fang
Förderung
- Tian Yuan Mathematical Foundation
Zitieren
APA
Wu, Y., Guo, J., Zhang, Y., Zhao, R., Luo, W., & Fang, C. (2026). Targeting PIN1 in Pancreatic Tumor Microenvironment with Peptide Amphiphiles Unleashes Immune Checkpoint Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503114
Vancouver
Wu Y, Guo J, Zhang Y, Zhao R, Luo W, Fang C. Targeting PIN1 in Pancreatic Tumor Microenvironment with Peptide Amphiphiles Unleashes Immune Checkpoint Therapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503114
BibTeX
@article{Wu2026,
author = {Wu, Yuanyuan and Guo, Jianan and Zhang, Yuwei and Zhao, Ruizhi and Luo, Wenhao and Fang, Chihua},
title = {Targeting PIN1 in Pancreatic Tumor Microenvironment with Peptide Amphiphiles Unleashes Immune Checkpoint Therapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503114}
}
EUVIMED